GlassScriptPhysician profile
Richard Boone
NPI 1023080215
$819.43
in general payments reported to CMS, 2019-2025
18 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.09 · 2024: $323 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $119.79 | 2024-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $95.27 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $86.48 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.56 | 2024 | Xifaxan, Trulance |
| Corium, LLC | $66.95 | 2024-2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $54.02 | 2025 | |
| Glaxosmithkline, LLC. | $47.14 | 2024 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $40.74 | 2024-2025 | Voquezna |
| Abbvie INC. | $35.58 | 2025 | |
| Exact Sciences Corporation | $33.84 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $31.18 | 2024 | Prolia, Evenity, Repatha |
| Inspire Medical Systems, INC. | $24.56 | 2025 | Inspire |
| Ossur Americas, INC. | $21.80 | 2025 | |
| Genentech USA, INC. | $19.09 | 2019 | |
| Axsome Therapeutics, INC. | $15.07 | 2025 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $14.47 | 2025 | Gemtesa |
| Paratek Pharmaceuticals, INC. | $14.32 | 2024 | Nuzyra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.57 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Boone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.